Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

AC Immune (ACIU) EBIAT (2016 - 2026)

AC Immune has reported EBIAT over the past 11 years, most recently at -$18.9 million for Q1 2026.

  • Quarterly EBIAT rose 10.7% to -$18.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$82.3 million through Mar 2026, down 41.87% year-over-year, with the annual reading at -$84.6 million for FY2025, 61.59% down from the prior year.
  • EBIAT was -$18.9 million for Q1 2026 at AC Immune, down from -$18.0 million in the prior quarter.
  • Over five years, EBIAT peaked at $6.4 million in Q3 2024 and troughed at -$25.6 million in Q2 2025.
  • The 5-year median for EBIAT is -$18.9 million (2023), against an average of -$17.4 million.
  • Year-over-year, EBIAT skyrocketed 137.05% in 2024 and then crashed 412.11% in 2025.
  • A 5-year view of EBIAT shows it stood at -$19.5 million in 2022, then soared by 72.52% to -$5.3 million in 2023, then crashed by 237.17% to -$18.0 million in 2024, then increased by 0.27% to -$18.0 million in 2025, then dropped by 5.1% to -$18.9 million in 2026.
  • Per Business Quant, the three most recent readings for ACIU's EBIAT are -$18.9 million (Q1 2026), -$18.0 million (Q4 2025), and -$19.8 million (Q3 2025).